Drug Profile
Levobunolol - AbbVie
Alternative Names: AG 901; AGN 101291; AGN 101291AL; Betagan; Bunolgan; Levobunolol ophthalmic - AbbVie; Mirol; Vistagan; W 7000ALatest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie; Kaken Pharmaceutical; Kyorin Pharmaceutical
- Class Antiglaucomas; Antihypertensives; Propanolamines; Small molecules
- Mechanism of Action Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Glaucoma
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 20 Mar 2001 Launched for Glaucoma in Japan (Ophthalmic)
- 28 Jun 2000 New profile